Gastroesophageal Reflux Disease (GERD) Market Players:
- AstraZeneca PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eisai Co., Ltd.
- GSK plc.
- Takeda Pharmaceutical Company Limited.
- Ironwood Pharmaceuticals, Inc.
- Johnson & Johnson Services, Inc.
- SFJ Pharmaceuticals
- Sebela Pharmaceuticals
- Phathom Pharmaceuticals, Inc.
- Camber Pharmaceuticals, Inc.
Key players in the market are currently engaged in extensive R&D cohorts to expand their pipeline. They are introducing new safer and long-acting alternatives for better consumer satisfaction and wider adoption. For instance, in April 2024, Onconic Therapeutics gained marketing clearance from the Ministry of Food and Drug Safety (MFDS) of Korea for its next-generation potassium competitive blocker (P-CAB), JAQBO (zastaprazan citrate). This new drug is clinically proven to deliver 97.9% healing for adult GERD patients, just within 8 weeks. Similarly, in December 2024, HK inno.N Corporation announced the commercial launch of its K-CAB (tegoprazan) for GERD in 6 additional Latin American countries. Such key players are:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of GERD is evaluated at USD 6.66 billion.
The global GERD market size was worth around USD 6.24 billion in 2025 and is set to register a CAGR of more than 7.5%, exceeding USD 12.86 billion revenue by 2035.
North America in the gastroesophageal reflux disease market is predicted to hold a 35% share by 2035, driven by the rising patient population prone to gastrointestinal issues.
Key players in the market include Passport Inc., BondTraffic Solutions, APCOA Parking Deutschland, TIBA Parking, DELOPT, YourParkingSpace, FlashParking Inc., International Business Machines Corporation, Infocomm Group LLC.
